JD HEALTH's stock soared 5.01% during intraday trading on Wednesday, driven by positive analyst sentiment and technological advancements in its healthcare platform.

The surge follows a research report from BOCI which highlighted JD Health's strong quarterly performance with 25% year-over-year revenue growth and a record adjusted net profit margin of 10.6%. The broker raised its target price from 45 HKD to 47 HKD while maintaining a Buy rating on the stock.

Further supporting the bullish sentiment is the company's announcement of a major 2.0 upgrade to its proprietary medical large language model, incorporating multimodal perception and deep retrieval technology to enhance clinical decision support. This comes alongside robust full-year financial results showing 26.2% revenue growth, margin expansion, and a 29.2% increase in net profit, marking three consecutive years of profitability growth.